All News
Filter News
Found 101 articles
-
At the moment, eight clinical trials are currently being carried out to determine if the link between melatonin and the novel coronavirus is legitimate.
-
Despite some setbacks, the company anticipates its vaccine could be available for use in the United Kingdom within the next several weeks.
-
145 hospitals and clinics received their first batch of Pfizer-BioNTech's coronavirus vaccine today.
-
AstraZeneca and the University of Oxford published an interim analysis of their four Phase III clinical trials of AZD1222, their COVID-19 vaccine.
-
Canada to receive early delivery of Pfizer-BioNTech COVID-19 vaccine
12/7/2020
The Government of Canada is delivering on its commitment to ensure that Canadians have access to safe and effective COVID-19 vaccines as soon as possible. The Honourable Anita Anand, Minister of Public Services and Procurement, announced today that following successful negotiations, Canada will receive up to 249,000 doses
-
Biopharma companies who have COVID-19 vaccines in development, have astonished skeptics by the speed with which they have developed vaccines.. But now comes an even more daunting challenge—scaling up manufacturing and distribution.
-
Another clinical study could confirm the 90% efficacy data that stemmed from accidental use of a half-dose in an arm of its Phase III trial.
-
As expected after Pfizer and BioNTech announced their COVID-19 vaccine Phase III trial had completed and demonstrated a 95% efficacy rate, the companies plan to apply for an Emergency Use Authorization (EUA) with the FDA.
-
The looming question is: when will the public be able to start getting the vaccines?
-
In addition to coming sooner than expected, the results are even better than expected. The trial hit all primary efficacy endpoints.
-
Only a week after Pfizer and BioNTech’s preliminary data readout of its COVID-19 vaccine suggested a 90% efficacy rate, Moderna reported interim efficacy data for its vaccine of 94.5%.
-
Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study
11/16/2020
Moderna intends to submit for an Emergency Use Authorization (EUA) with U.S. FDA in the coming weeks and expects the EUA to be based on the final analysis of 151 cases and a median follow-up of more than 2 months
-
The Oxford and AstraZeneca co-developed COVID-19 vaccine could be one of the first vaccines submitted for regulatory approval, alongside Pfizer and BioNTech’s vaccine candidate BNT162b2.
-
There is an impressive amount of technological ingenuity – mRNA, monoclonal antibodies and more traditional formats – being thrown at the development of a vaccine against COVID-19.
-
Fauci said the first COVID-19 vaccines could ship late December or early January.
-
To date, all the major clinical trials of vaccines against COVID-19 have been in adults.
-
J&J did not disclose much information about the unexplained illness, stating, “We must respect this participant’s privacy. We’re also learning more about this participant’s illness, and it’s important to have all the facts before we share additional information.”
-
The sticking point for the White House is a provision in the guidance that calls for vaccine manufacturers to follow people participating in late-stage clinical trials for a median of at least two months, starting after they receive a second vaccine shot.
-
If that guidance comes to pass, it would delay potential EUA of a vaccine until the end of 2020 or early 2021 – well after the Nov. 3 election.
-
Although the updated guidance has largely remained under wraps, sources who spoke to The Washington Post hinted that the new rules would make it more difficult for an EUA to be granted to a vaccine ahead of Nov. 3, the day of the U.S. elections.